SAN
DIEGO, Jan. 10, 2023 /PRNewswire/ -- Evofem
Biosciences, Inc. (OTCQB: EVFM) today announced that
Phexxi® (lactic acid, citric acid, potassium
bitartrate) has been added to the Costco Member Prescription
Program, giving millions of additional women access to this
innovative hormone-free contraceptive.
"We are pleased to partner with Costco, the largest warehouse
club and third-largest retailer in America, to expand Phexxi's
footprint in the cash space," said Saundra Pelletier, Chief
Executive Officer of Evofem. "This program enables Costco members
with no insurance or whose plans have denied coverage to fill their
Phexxi prescriptions at a reduced cost."
The Costco Member Prescription Program is a prescription drug
discount card program that provides eligible Costco members and
their eligible dependents the ability to obtain lower prices on
Phexxi and other participating drugs at participating
pharmacies.
Costco members who are uninsured and want to pay cash for their
Phexxi prescription, or who have been denied coverage by their
insurer, may use this program to fill their Phexxi prescriptions
for less than the typical cash pay cost.
The pricing available through the discount card applies at their
local Costco pharmacies, Costco mail order and thousands of
participating neighborhood pharmacies.
About Evofem
Evofem Biosciences, Inc., is developing and commercializing
innovative products to address unmet needs in women's sexual and
reproductive health. The Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid and potassium
bitartrate), is a hormone-free, on-demand prescription
contraceptive vaginal gel. It comes in a box of 12 pre-filled
applicators and is applied 0-60 minutes before each act of
sex. Learn more
at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of the safe harbor for forward-looking statements
provided by Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
including, without limitation statements regarding the impact of or
expectations relating to the availability of Phexxi through Costco.
Various factors could cause actual results to differ materially
from those discussed or implied in the forward-looking statements,
including market and other conditions, and you are cautioned not to
place undue reliance on these forward-looking statements, which are
current only as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties.
Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements, or that could impair the value of Evofem Biosciences'
assets and business, are disclosed in the Company's SEC filings,
including its Annual Report on Form 10-K for the year
ended December 31, 2021, filed with the SEC on March 10,
2022, its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2022 filed with the SEC
on January 6, 2023 and any subsequent filings. All
forward-looking statements are expressly qualified in their
entirety by such factors. The Company does not undertake any duty
to update any forward-looking statement except as required by
law.
Investor Contact
Amy
Raskopf
SVP, Investor Relations
araskopf@evofem.com
(917) 673-5775
Media Contact
media@evofem.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/costco-adds-phexxi-to-member-prescription-program-301717100.html
SOURCE Evofem Biosciences, Inc.
